Company news

Ucb S.A. news in 2026

Ucb S.A.'s news releases, calls and decks from 2026, newest first.

View company

UCB announces new data at EADV 2026 supporting earlier use of BIMZELX (bimekizumab) for treating hidradenitis suppurativa

September 30, 2026

UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG

September 29, 2026

UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)

September 9, 2026

UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing

August 31, 2026

Transparency notification Wellington Management Group LLP

August 31, 2026

Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome

August 5, 2026

UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase

July 30, 2026

UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026

July 8, 2026

FASTRAX working session highlights progress in axSpA diagnosis

July 3, 2026

UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline

June 17, 2026

UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite

June 9, 2026

UCB - EULAR 2026, Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

June 5, 2026

New EULAR 2026 data show CIMZIA (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels

June 5, 2026

BIMZELX(bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA

June 3, 2026

UCB completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science

June 2, 2026

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

June 1, 2026

Financial Reporting Document

May 20, 2026

Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies

May 7, 2026

UCB announces acquisition of IMIDomics Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases

May 4, 2026

UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers

May 3, 2026

UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)

May 1, 2026

General Meeting of Shareholders 2026

April 30, 2026

UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science

April 17, 2026

UCB - Acquisition of own shares

April 13, 2026

Acquisition of own shares

April 10, 2026

UCB - Convening Notice to the General Meeting of the Shareholders 2026

March 27, 2026

Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs

March 24, 2026

Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees

March 13, 2026

UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody

March 3, 2026

Decks in 2026